Gotham Asset Management’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-13,327
Closed -$174K 1067
2020
Q3
$174K Buy
+13,327
New +$169K 0.01% 953
2019
Q2
Sell
-20,055
Closed -$666K 1234
2019
Q1
$666K Buy
20,055
+5,145
+35% +$157K 0.01% 771
2018
Q4
$433K Sell
14,910
-30,719
-67% -$1.11M 0.01% 793
2018
Q3
$2.1M Buy
45,629
+21,878
+92% +$973K 0.03% 487
2018
Q2
$888K Sell
23,751
-9,220
-28% -$311K 0.01% 606
2018
Q1
$974K Sell
32,971
-111,800
-77% -$3.78M 0.01% 611
2017
Q4
$4.97M Sell
144,771
-74,321
-34% -$2.51M 0.07% 354
2017
Q3
$7.93M Sell
219,092
-39,720
-15% -$1.13M 0.12% 275
2017
Q2
$6.69M Sell
258,812
-90,450
-26% -$1.92M 0.09% 308
2017
Q1
$6.71M Buy
349,262
+60,220
+21% +$1.07M 0.09% 322
2016
Q4
$4.82M Sell
289,042
-132,686
-31% -$2.4M 0.06% 385
2016
Q3
$8.68M Buy
421,728
+60,898
+17% +$1.54M 0.11% 262
2016
Q2
$11M Buy
360,830
+159,303
+79% +$5.53M 0.13% 252
2016
Q1
$7.54M Buy
201,527
+5,163
+3% +$195K 0.08% 341
2015
Q4
$8.47M Buy
+196,364
New +$8.3M 0.09% 321
2015
Q1
Sell
-568,865
Closed -$19.4M 983
2014
Q4
$19.4M Sell
568,865
-300,666
-35% -$10.7M 0.16% 218
2014
Q3
$33.5M Sell
869,531
-247,820
-22% -$9.25M 0.33% 95
2014
Q2
$43.5M Sell
1,117,351
-88,748
-7% -$3.3M 0.54% 25
2014
Q1
$41.2M Sell
1,206,099
-110,215
-8% -$3.41M 0.62% 2
2013
Q4
$27.6M Buy
1,316,314
+350,327
+36% +$8.86M 0.66% 3
2013
Q3
$22.7M Buy
965,987
+413,312
+75% +$11.7M 0.74% 7
2013
Q2
$14.8M Buy
+552,675
New +$16M 0.64% 19

Other funds holding MYGN

Gotham Asset Management's MYGN Position: Q4 2020 in Review

Gotham Asset Management sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 13,327 shares — an estimated $174K sold.

Gotham Asset Management first reported a position in MYGN in Q2 2013 and held it in 22 quarters. The position peaked at $43.5M in Q2 2014. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.

  • Gotham Asset Management reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
  • Gotham Asset Management sold 13,327 Myriad Genetics shares in Q4 2020, an estimated $174K.
  • Gotham Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 22 quarters.
  • Gotham Asset Management's Myriad Genetics position peaked at $43.5M in Q2 2014.
  • 187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.

Based on Gotham Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.